Want to see SE:IVACC full AI Analyst Report?
IVACC Stock Chart & Stats
kr1.05
>-kr0.01(-0.47%)
At close: 4:00 PM EDT
kr1.05
>-kr0.01(-0.47%)
Day’s Range― - ―
52-Week Rangekr0.57 - kr1.46
Previous CloseN/A
Volume77.75K
Average Volume (3M)262.96K
Market Cap
kr344.22M
Enterprise Valuekr317.65
Total Cash (Recent Filing)kr127.64M
Total Debt (Recent Filing)kr866.00K
Price to Earnings (P/E)―
Beta0.46
Next Earnings
Nov 12, 2026EPS Estimate
-0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.26
Shares Outstanding340,813,200
10 Day Avg. Volume182,455
30 Day Avg. Volume262,961
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)1.00
Price to Sales (P/S)13.68
P/FCF Ratio-4.11
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.22
Revenue Forecast (FY)kr21.60M
Bulls Say, Bears Say
Bulls Say
Low Financial LeverageA conservative capital structure limits debt-related solvency risk and reduces exposure to refinancing or interest burdens. Substantial equity relative to assets provides financial runway for continued vaccine development and commercialization, even though it does not eliminate the need for eventual funding.
Commercialized Animal-health PlatformThe marketed canine vaccine gives Intervacc an established commercial product rather than a purely pre-revenue pipeline. Its focused veterinary-health specialization can support regulatory know-how, customer relationships, and future expansion if additional products or geographies gain approval.
Earlier Revenue ExpansionStrong revenue expansion across several earlier annual periods indicates that the company has demonstrated an ability to grow commercial activity when market uptake and product access support it. That history provides a foundation for recovery if recent weakness proves temporary and margins improve.
Bears Say
Persistent UnprofitabilityNegative gross profit and substantial operating losses show that the current product economics do not yet cover the company’s cost base. Persistent net losses weaken internal funding capacity and make a durable path to profitability dependent on stronger sales, improved margins, or lower operating spending.
Ongoing Cash BurnRepeated negative operating and free cash flow means the business is not currently self-funding its operations or development investment. Continued cash burn can consume the available equity cushion over time and may require additional financing if operating performance does not improve.
Recent Revenue WeaknessThe latest revenue decline is concerning because it follows a period of earlier growth and occurs alongside deeply negative margins. Without renewed demand or broader commercialization, weaker sales can reduce operating leverage and prolong losses, delaying the transition toward a sustainable business model.
IVACC FAQ
What was Intervacc AB’s price range in the past 12 months?
Intervacc AB lowest stock price was kr0.57 and its highest was kr1.46 in the past 12 months.
What is Intervacc AB’s market cap?
Intervacc AB’s market cap is kr344.22M.
When is Intervacc AB’s upcoming earnings report date?
Intervacc AB’s upcoming earnings report date is Nov 12, 2026 which is in 52 days.
How were Intervacc AB’s earnings last quarter?
Intervacc AB released its earnings results on Aug 20, 2026. The company reported -kr0.06 earnings per share for the quarter, missing the consensus estimate of -kr0.05 by -kr0.01.
Is Intervacc AB overvalued?
According to Wall Street analysts Intervacc AB’s price is currently Overvalued.
Does Intervacc AB pay dividends?
Intervacc AB does not currently pay dividends.
What is Intervacc AB’s EPS estimate?
Intervacc AB’s EPS estimate is -0.06.
How many shares outstanding does Intervacc AB have?
Intervacc AB has 340,813,200 shares outstanding.
What happened to Intervacc AB’s price movement after its last earnings report?
Intervacc AB reported an EPS of -kr0.06 in its last earnings report, missing expectations of -kr0.05. Following the earnings report the stock price went down -1.075%.
Which hedge fund is a major shareholder of Intervacc AB?
Currently, no hedge funds are holding shares in SE:IVACC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Intervacc AB
Intervacc AB (publ) is a Swedish biotechnology company primarily engaged in the research and development of innovative vaccines designed to combat bacterial infections in animal health. The firm's vaccine pipeline targets various animals, including horses, piglets, and dairy cows, with its key product, Strangvac, specifically developed to prevent equine strangles. Beyond its current offerings, Intervacc is also advancing vaccines against Streptococcus suis and Staphylococcus aureus infections. In addition to vaccine development, the company distributes veterinary medicines and provides essential diagnostic services in veterinary bacteriology to clinics and stud farms. Headquartered in Hägersten, Sweden, Intervacc serves customers across the Nordic countries and the Baltic states.
Technical Analysis
Alligator Bioscience AB
―
BioInvent International AB
―
ExpreS2ion Biotech Holding AB
―
Immunicum AB
―
Cantargia AB
―